Fibrosis meeting, Bergen 2022
Symposium on tumor and tissue fibrosis
Photo:
Torstein Ravnskog/UiB
Main content
Updated: 16.10.2023 (First published: 15.06.2022)
Symposium on tumor and tissue fibrosis
Bergen, Norway
Venue: June 9-10, 2022 - Max 60 attendants (including speakers) at Hotel Terminus.
There will also be a live streaming of the event on Zoom.
Organizer: Donald Gullberg
All the sessions will be in-person, but also streamed live as Zoom webinar, and will be recorded and placed on a private YouTube channel. A link to the videos on YouTube will be sent to all the participants of the symposium.
Thursday June 9 | ||
Local time Bergen, Norway (CEST*, UTC+2) | Speakers Title | |
9.00 - 9.40 | Donald Gullberg, University of Bergen What is a fibroblast? | |
9.50 -10.30 | Ritva Heljasvaara, University of Oulu Collagens XIII and XV in fibrosis | |
10.40-11.00 | Coffee | |
11.00-11.40 | Sergey Plotnikov, UoT, Canada Cytoskeleton protection by formin mDia1 is essential for cell responses to profibrotic stimuli | |
11.50-13.00 | Lunch | |
13.50-14.30 | Roger Oria-Fernandez, UCSF Mechanotransduction in cancer | |
14.40-15.20 | Chris McCulloch, UoT, Canada Role of DDR1 in fibrosis | |
15.40-16.00 | Coffee | |
16.10-16.50 | Tom Barker, University of Virginia The Matrix: a major driver and therapeutic target of Fibrosis | |
17.00-17.40 | Andreas Romaine, UiO, Norway Heart fibrosis | |
19.00 | Conference Dinner | |
Friday June 10 | ||
9.00 - 9.40 | Ronen Schuster, CytoReason, Tel Aviv High content approach to map fibroblast-macrophage interactions | |
9.50-10.30 | Andrew Leask, USask, Canada Turning it up to Eleven: Targeting the microenvironment in fibrotic condition | |
10.40-11.00 | Coffee | |
11.00-11.40 | Daniela Costea, University of Bergen CAF heterogeneity in squamous cell carcinoma | |
11.50-12.30 | Daniela Costea, Harsh Dongre and Stian Tornaas, University of Bergen Hyperion demonstration | |
12.40-13.20 | Coffee | |
13.20-14.00 | Roya Navab, University of Toronto CAF heterogeneity in drug-tolerant persister non-small cell lung cancer tumor | |
14.10-14.50 | Humphrey Gardner, Roivant Sciences, Boston Stromal phenotypic markers and disease outcome in solid tumors | |
15.00-15.40 | Erine Budi, Pliant Therapeutics, San Francisco Development of Integrin Inhibitors to Treat Fibrotic Disease | |
15.50-16.00 | Coffee | |
*) CEST = Central European Summer Time
Things to do in Bergen